Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU7-176P is classified as a pseudogene related to the U7 small nuclear RNA family. U7 snRNA is normally involved in the processing of histone pre-mRNA, but pseudogenes such as RNU7-176P contain mutations and other sequence disruptions that prevent them from coding any functional RNA product[7][5]. Pseudogenes are typically remnants of ancestral genes that have lost their functional activity due to mutation and do not participate in normal cellular processes or disease pathways[4][7]. While rare cases exist of pseudogenes exerting regulatory effects in the genome, there is no evidence that RNU7-176P is transcribed, translated, or functionally active[7][6][5]. It is not considered a drug target, receptor, enzyme, or biomarker and is primarily of interest as a genomic annotation. There is nothing misspelled, but the target is not a functional gene, receptor, or protein, and therefore should not be considered a therapeutic target by standard definitions[6][7][5].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U7 small nuclear 176 pseudogene (RNU7-176P).